Perinatology and pediatric.Ukraine. 2017.4(72):54-59; doi 10.15574/PP.2017.72.54

Lymanska A. Yu., Davydova Yu. V.
SI «Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine», Kyiv, Ukraine

Objective: to investigate the blood coagulation system and platelet aggregation before and after the use of Latren^®; to evaluate the reduction of complaints (normalization of colour, sensitivity enhancement and lack of pain in fingers of the upper limbs) in response to treatment.
Material and methods. In total 27 women with systemic lupus erythematosus were examined who visited the SI «Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine» for the purpose of preconceptional counseling and control of the autoimmune process activity. All women were administered the drug Latren^® according to the schedule of 100 mg (200 ml) intravenous infusion once daily during 12 days. The blood coagulation system and the platelet aggregation was studied before and after the treatment of the drug Latren^® (manufactured by «Yuria-Pharm») using the BIOLA laser aggregometer with inducers.
Results. The drug Latren^®, having an effect upon the platelet homeostasis and reducing the aggregation of platelets and erythrocytes, boosts the plasticity of blood cells, which is be critical to improving microcirculation, insofar as it offers the possibility to intensify nutritional circulation due to the fact that erythrocytes and leukocytes gain the capacity to pass through free haemocapillaries. Latren^® suppresses the synthesis of fibrinogen, thrombin and antiplasmin, increases the serum concentration of plasminogen activator, which resulting in improvement of blood viscosity and normalization of the coagulation function. The above mentioned affects the blood circulation speed in the microcirculation, which directly depends upon the serum concentration of fibrinogen. The balanced isoosmolar electrolyte solution, complexed with Latren^® (manufactured by «Yuria-Pharm»), potentiates the action of pentoxifylline in angioneuropathies, which are characteristic of Raynaud's syndrome, which, in turn, increases the treatment efficacy.
Conclusions. Thus, the drug Latren^® has the necessary haemorheological properties to correct impaired circulation in the microvasculature, which significantly improves the general status of women with Raynaud's syndrome on the background of an autoimmune disease.
Key words: autoimmune diseases, correction of microvascular blood flow, Latren^®.

References

1. Korkushko OV, Zharynova VIu, Bodretska LA. (2013). Vplyv pentoksyfilinu na pokaznyky hemovaskuliarnoho homeostazu, tsentralnoi hemodynamiky, riven markeriv zapalennia i vyrazhenist apoptozu u patsiientiv pokhyloho viku z IKhS. Krovoobih ta hemostaz. 3—4: 22—27.

2. Neirotti M, Longo F, Molaschi M et al. (1987). Functional vascular disorders: Treatment with pentoxifylline. Angiology. 38(8): 575—580. https://doi.org/10.1177/000331978703800801; PMid:3631642

3. Herrick A. (2017, Dec). Evidence-based management of Raynaud's phenomenon. Ther Adv Musculoskelet Dis. 9(12): 317—329. Published online 2017 Nov. 20. https://doi.org/10.1177/1759720X17740074.

4. Herrick AL. (2005). Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford). 44(5): 587—596. https://doi.org/10.1093/rheumatology/keh552; PMid:15741200

5. Lewis T. (1929). Experiments relating to the peripheral mechanisms involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart. 15(7): 101.

6. Mulleman D., Mammou S., Gri' Ioul et al. (2006, May). Pathophysiology of disk-related low back pain and sciatica. II. Evidence supporting treatment with TNF-alpha antagonists. Joint Bone Spine. 73(3): 270—277. Epub 2005. Jun 22.

7. Meininger V, Asselain B, Guillet P et al. (2006, Jan 10). Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Pentoxifylline European Group. Neurology. 66(1): 88—92. https://doi.org/10.1212/01.wnl.0000191326.40772.62; PMid:16401852

8. Wei T, Sabsovich I, Guo TZ et al. (2009, Mar). Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur J Pain. 13(3): 253—262. Epub. 2008. Jun 12.

9. Raynaud M. (1862). Local Asphyxia and Symmetrical Gangrene of the Extremities. London: New Sydenham Society.

10. Bakst R, Merola JF, Franks AGJr, Sanchez M. (2008). Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol. 59(4): 633—653. https://doi.org/10.1016/j.jaad.2008.06.004; PMid:18656283

11. Wigley FM, Flavahan NA. (2016). Raynaud's phenomenom. N Eng J Med. 375: 556—565. https://doi.org/10.1056/NEJMra1507638; PMid:27509103